US 12,071,456 B2
Extended recombinant polypeptides and compositions comprising same
Volker Schellenberger, Palo Alto, CA (US); Joshua Silverman, Los Altos Hills, CA (US); Chia-wei Wang, Santa Clara, CA (US); Benjamin Spink, San Carlos, CA (US); Willem P. Stemmer, Los Gatos, CA (US); Nathan Geething, Natick, MA (US); Wayne To, Fremont, CA (US); and Jeffrey L. Cleland, San Carlos, CA (US)
Assigned to AMUNIX PHARMACEUTICALS, INC., South San Francisco, CA (US)
Filed by AMUNIX PHARMACEUTICALS, INC., South San Francisco, CA (US)
Filed on Jan. 15, 2021, as Appl. No. 17/150,426.
Application 17/150,426 is a continuation of application No. 15/887,313, filed on Feb. 2, 2018, granted, now 10,961,287.
Application 15/887,313 is a continuation of application No. 15/154,223, filed on May 13, 2016, granted, now 9,926,351, issued on Mar. 27, 2018.
Application 15/154,223 is a continuation of application No. 14/168,973, filed on Jan. 30, 2014, granted, now 9,371,369, issued on Jun. 21, 2016.
Application 14/168,973 is a continuation of application No. 12/699,761, filed on Feb. 3, 2010, granted, now 8,673,860, issued on Mar. 8, 2014.
Claims priority of provisional application 61/281,109, filed on Nov. 12, 2009.
Claims priority of provisional application 61/280,955, filed on Nov. 10, 2009.
Claims priority of provisional application 61/280,956, filed on Nov. 10, 2009.
Claims priority of provisional application 61/245,490, filed on Sep. 24, 2009.
Claims priority of provisional application 61/243,707, filed on Sep. 18, 2009.
Claims priority of provisional application 61/236,836, filed on Aug. 25, 2009.
Claims priority of provisional application 61/236,493, filed on Aug. 24, 2009.
Claims priority of provisional application 61/268,193, filed on Jun. 8, 2009.
Claims priority of provisional application 61/185,112, filed on Jun. 8, 2009.
Claims priority of provisional application 61/149,669, filed on Feb. 3, 2009.
Prior Publication US 2021/0277074 A1, Sep. 9, 2021
Int. Cl. C07K 14/47 (2006.01); C07K 14/00 (2006.01); C07K 14/545 (2006.01); C07K 14/605 (2006.01); C07K 14/61 (2006.01); C07K 14/745 (2006.01); C12N 9/64 (2006.01)
CPC C07K 14/47 (2013.01) [C07K 14/001 (2013.01); C07K 14/545 (2013.01); C07K 14/605 (2013.01); C07K 14/61 (2013.01); C07K 14/745 (2013.01); C12N 9/6437 (2013.01); C12N 9/644 (2013.01); C07K 2319/31 (2013.01); C07K 2319/35 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method of treating a disease, disorder or condition, comprising administering a therapeutically effective dose of a pharmaceutical composition to a subject in need thereof,
wherein the pharmaceutical composition comprises a fusion protein and one or more pharmaceutically acceptable excipients,
wherein the fusion protein comprises an extended recombinant polypeptide linked to a biologically active protein (BP),
wherein the extended recombinant polypeptide comprises an amino acid sequence which has at least 90% sequence identity to SEQ ID NOs: 205, 208, 211, 461-465, 467-477, 479, 480-485, 487-489, 491-504, 699, 772, or 793,
wherein the extended recombinant polypeptide comprises a motif of SEQ ID NO: 190, SEQ ID NO: 192, or SEQ ID NO: 193,
wherein the disease, disorder or condition is type 1 diabetes, type 2 diabetes, obesity, hyperglycemia, hyperinsulinemia, decreased insulin production, insulin resistance, syndrome X, excessive appetite, insufficient satiety, glucagonomas, dyslipidemia, retinal neurodegenerative processes, Factor VII deficiency, Factor X deficiency, Factor XII deficiency, hemophilia A, hemophilia B, Von Willebrand's disease, hypertension, acute coronary syndrome, rheumatoid arthritis, reperfusion injury following ischemia, growth-hormone deficiency, Turner's Syndrome, Prader-Willi Syndrome, idiopathic short stature, AIDS wasting, multiple sclerosis, Crohn's disease, ulcerative colitis, muscular dystrophy, or surgical bleeding.